Want to see HK:3320 full AI Analyst Report?
3320 Stock Chart & Stats
HK$4.61
HK$0.05(0.94%)
At close: 4:00 PM EST
HK$4.61
HK$0.05(0.94%)
Day’s Range― - ―
52-Week RangeHK$4.22 - HK$6.53
Previous CloseN/A
Volume6.08M
Average Volume (3M)13.76M
Market Cap
HK$30.47B
Enterprise ValueHK$162.34K
Total Cash (Recent Filing)HK$31.05B
Total Debt (Recent Filing)HK$104.87B
Price to Earnings (P/E)6.8
Beta0.82
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.49%
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume13,454,154
30 Day Avg. Volume13,759,791
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Business ModelVertical integration across distribution, retail and manufacturing creates durable revenue diversification and supply‑chain control. This reduces dependence on a single channel, enables cross‑selling and inventory efficiency, supporting stable cash flow and resilience over months.
Strong Cash GenerationConsistently strong operating and free cash flow relative to earnings improves financial flexibility for capex, dividends and debt servicing. Reliable cash conversion supports strategic investments and cushions the business against cyclical pressures over the medium term.
Steady Revenue And Operating ProfitabilityReturn to mid‑single‑digit revenue growth and stable operating margins indicate underlying demand and operational stability. Consistent top‑line expansion plus modest operating margin improvement supports sustainable earnings power and reinvestment capacity over 2–6 months.
Bears Say
Very Thin Net MarginsNet margins near 1–1.5% leave little room for error: small cost increases or pricing pressure materially reduce profits. Limited bottom‑line leverage constrains retained earnings, weakens return sensitivity, and hampers long‑term capacity to build equity organically.
Rising LeverageMaterial rise in leverage increases interest burden and financial risk, reducing flexibility for M&A or capital spending. Elevated debt levels amplify downside in an adverse environment and make the company more sensitive to credit conditions over the medium term.
Low Debt Coverage By Cash FlowOperating cash flow covers a tiny fraction of total debt, limiting the company’s ability to deleverage quickly. This structural cash‑coverage gap constrains capital allocation choices and raises refinancing or liquidity risk if market conditions tighten.
China Resources Pharmaceutical Group Ltd. News
3320 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was HK$4.22 and its highest was HK$6.53 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is HK$30.47B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
Currently, no data Available
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Overvalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. pays a Quarterly dividend of HK$0.139 which represents an annual dividend yield of 4.49%. See more information on China Resources Pharmaceutical Group Ltd. dividends here
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in HK:3320
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
4.49%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―